MYC Drives Progression of Small Cell Lung Cancer to a Variant Neuroendocrine Subtype with Vulnerability to Aurora Kinase InhibitionGürkan Mollaoglu, Trudy G. Oliver, Matthew R. Guthrie et al.|Cancer Cell|2017Cited by 607
Lsd1 as a therapeutic target in Gfi1-activated medulloblastomaCatherine Lee, Robert J. Wechsler‐Reya, Vasilisa A. Rudneva et al.|Nature Communications|2019Cited by 84
The long noncoding RNA <i>lnc-HLX-2-7</i> is oncogenic in Group 3 medulloblastomasKeisuke Katsushima, Ranjan J. Perera, Bongyong Lee et al.|Neuro-Oncology|2020Cited by 42
Glioblastoma stem cells reprogram chromatin in vivo to generate selective therapeutic dependencies on DPY30 and phosphodiesterasesDeobrat Dixit, Jeremy N. Rich, Shira Yomtoubian et al.|Science Translational Medicine|2022Cited by 37
Isocitrate dehydrogenase 1 primes group-3 medulloblastomas for cuproptosisDerek Dang, Sriram Venneti, Akash Deogharkar et al.|Cancer Cell|2025Cited by 21